The Effect of Continuous Renal Replacement Therapy on the Efficiency of Extracorporeal CO2 Removal

Sponsor
Southeast University, China (Other)
Overall Status
Recruiting
CT.gov ID
NCT05989971
Collaborator
(none)
10
1
7.3
1.4

Study Details

Study Description

Brief Summary

In the design of extracorporeal carbon dioxide removal (ECCO2R) combined with continuous renal replacement therapy (CRRT) equipment, in model of continuous veno-venous hemofiltration (CVVH) , the HCO3- concentration in the pre membrane lung blood is diluted by the replacement solution, and a decrease in HCO3- leads to a decrease in PCO2. On the other hand, in continuous veno-venous hemodialysis (CVVHD), HCO3- in post membrane blood will exchange interaction. The exchange results of HCO3- determine the impact of CVVHD on the CO2 removal efficiency of the ECCO2R combined CRRT system. This study aims to investigate the effects of CVVH and CVVHD on in vitro CO2 clearance efficiency.

Condition or Disease Intervention/Treatment Phase
  • Other: continuous renal replacement therapy

Detailed Description

In the design of extracorporeal carbon dioxide removal (ECCO2R) combined with continuous renal replacement therapy (CRRT) equipment, the pre dilution replacement solution for continuous veno-venous hemofiltration (CVVH) enters the extracorporeal bloodstream upstream of the membrane lung, so the HCO3- concentration in the pre membrane lung blood is diluted by the replacement solution. HCO3- and dissolved CO2 are in a dynamic and rapid equilibrium state, and a decrease in HCO3- leads to a decrease in PCO2. On the other hand, in continuous veno-venous hemodialysis (CVVHD), the blood after the membrane needs to undergo material exchange with the dialysate through a filter. The dialysate is usually HCO3- with normal plasma concentration, so HCO3- in post membrane blood will exchange interaction. The exchange results of HCO3- determine the impact of CVVHD on the CO2 removal efficiency of the ECCO2R combined CRRT system. This study aims to investigate the effects of CVVH and CVVHD on in vitro CO2 clearance efficiency.

Study Design

Study Type:
Observational
Anticipated Enrollment :
10 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Effect of Continuous Renal Replacement Therapy on the Efficiency of Extracorporeal CO2 Removal
Actual Study Start Date :
Apr 24, 2023
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Extracorporeal carbon dioxide removal combined with continuous renal replacement therapy

extracorporeal carbon dioxide removal combined with continuous veno-venous hemofiltration or continuous veno-venous hemodialysis.CVVH and CVVHD set-up: predilution 30 ml/kg/h, dialysate dose 30 ml/kg/h, ultrafiltration rate was equal to the total rate of substitution fluid infusion.

Other: continuous renal replacement therapy
continuous veno-venous hemofiltration or continuous veno-venous hemodialysis set-up: predilution 30 ml/kg/h, dialysate dose 30 ml/kg/h, ultrafiltration rate was equal to the total rate of substitution fluid infusion

Outcome Measures

Primary Outcome Measures

  1. extracorporeal CO2 removal rate [after 30min of continuous renal replacement therapy]

    extracorporeal CO2 removal rate was calculated as the difference of total CO2 content before membrane lung and after hemofilter, and normalized to an inlet PCO2 of 45 mmHg

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Using Extracorporeal carbon dioxide removal combined with continuous renal replacement therapy

  • 18 years ≤ age ≤ 85 years;

Exclusion Criteria:
  • Severe hemodynamic instability (increased dosage of vasoactive drugs or MAP ≤ 65mmHg within two hours);

  • Severe electrolyte deficiency (including severe hyponatremia (blood sodium<130mmol/L) and hypokalemia (blood potassium<3.0mmol/L));

  • Participate in other intervention studies within 30 days;

  • Do not consent this research

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ling Liu Nanjing Jiangsu China 210009

Sponsors and Collaborators

  • Southeast University, China

Investigators

  • Study Director: Ling Liu, Zhongda Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ling Liu, deputy director, Southeast University, China
ClinicalTrials.gov Identifier:
NCT05989971
Other Study ID Numbers:
  • 20230731
First Posted:
Aug 14, 2023
Last Update Posted:
Aug 14, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 14, 2023